# Bluejay Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bluejay-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.bluejaytx.com
- Total disclosed funding: $203M
- Latest round: Series C (May 1, 2024)
- Investors on record: 13

## About

Founded in 2020 and based in California, US, Bluejay Therapeutics Inc. operates as a therapeutic medicine developer for treating infectious diseases such as HBV infection. In?December 2025, Mirum Pharmaceuticals, Inc., a portfolio company of?Frazier Healthcare Partners, New Enterprise Associates, Pappas Capital, RiverVest Ventures Partners, Novo Holdings, Deerfield Management, Oberland Capital, and Rock Springs Capital, will acquire Bluejay Therapeutics from Arkin Capital, InnoPinnacle, Octagon Capital Advisors, RiverVest Ventures Partners, Synergenics LLC, Yonghua Capital, Frazier Life Sciences Management, HBM Partners, Novo Holdings, RA Capital Management, T Rowe Price Advisory Services, Unicorn Capital, and Wellington Management?for USD 620 million.

The company offers two main product candidates: BJT-778, a human anti-HBsAg monoclonal antibody with a considerably better pharmacological profile than antibodies currently in development (potency, epitope, safety); and BJT-754, an oral curative HBsAg inhibitor that is the ideal combination partner.

The acquisition enables Mirum to add brelovitug, a late-stage hepatitis D therapy, strengthening its rare liver disease portfolio and pipeline.

## Funding rounds

- Series C, May 1, 2024, $182M — HBM Partners, Novo Holdings, Wellington Management, RA Capital Management, Unicorn Venture Capital, Arkin Capital, T Rowe Price Advisory Services, Octagon Capital Advisors, Frazier Life Sciences Management, Lp
- Series B, Aug 9, 2022, $21M — RiverVest Ventures Partners, Yonghua Capital, Arkin Capital, Octagon Capital Advisors, Synergenics LLC, InnoPinnacle International

## Investors

- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series B
- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series B
- Arkin Capital (https://capitalatlas.ai/funds/arkin-capital) — Series B, Series C
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series B, Series C
- Synergenics LLC — Series B
- InnoPinnacle International — Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- Novo Holdings — Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Unicorn Venture Capital (https://capitalatlas.ai/funds/unicorn-venture-capital) — Series C
- T Rowe Price Advisory Services — Series C
- Frazier Life Sciences Management, Lp — Series C